Coldstream Capital Management Inc. Buys Shares of 3,690 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Coldstream Capital Management Inc. bought a new stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCIFree Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 3,690 shares of the biopharmaceutical company’s stock, valued at approximately $264,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of Intra-Cellular Therapies by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 8,539,725 shares of the biopharmaceutical company’s stock valued at $444,834,000 after acquiring an additional 43,689 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of Intra-Cellular Therapies by 4.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,063,802 shares of the biopharmaceutical company’s stock valued at $107,503,000 after acquiring an additional 86,388 shares during the period. Wellington Management Group LLP increased its holdings in shares of Intra-Cellular Therapies by 6.7% in the 3rd quarter. Wellington Management Group LLP now owns 1,815,954 shares of the biopharmaceutical company’s stock valued at $94,593,000 after acquiring an additional 114,370 shares during the period. Norges Bank purchased a new position in shares of Intra-Cellular Therapies in the 4th quarter valued at $85,744,000. Finally, Polar Capital Holdings Plc increased its holdings in shares of Intra-Cellular Therapies by 150.0% in the 3rd quarter. Polar Capital Holdings Plc now owns 1,000,000 shares of the biopharmaceutical company’s stock valued at $52,090,000 after acquiring an additional 600,000 shares during the period. 92.33% of the stock is owned by institutional investors.

Intra-Cellular Therapies Stock Performance

ITCI stock opened at $65.54 on Monday. The business has a 50 day simple moving average of $68.89 and a 200-day simple moving average of $67.22. Intra-Cellular Therapies, Inc. has a 1 year low of $45.50 and a 1 year high of $84.89.

Intra-Cellular Therapies (NASDAQ:ITCIGet Free Report) last issued its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.15. The company had revenue of $144.90 million during the quarter, compared to analyst estimates of $141.41 million. Intra-Cellular Therapies had a negative return on equity of 18.49% and a negative net margin of 21.57%. The firm’s revenue for the quarter was up 52.0% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.46) earnings per share. As a group, equities research analysts predict that Intra-Cellular Therapies, Inc. will post -0.53 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Sharon Mates sold 20,565 shares of the stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $65.21, for a total value of $1,341,043.65. Following the completion of the transaction, the chief executive officer now directly owns 1,050,309 shares in the company, valued at $68,490,649.89. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Intra-Cellular Therapies news, CEO Sharon Mates sold 20,565 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $65.21, for a total transaction of $1,341,043.65. Following the transaction, the chief executive officer now directly owns 1,050,309 shares in the company, valued at $68,490,649.89. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Lawrence J. Hineline sold 13,132 shares of the company’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $66.60, for a total value of $874,591.20. Following the transaction, the chief financial officer now owns 29,700 shares in the company, valued at $1,978,020. The disclosure for this sale can be found here. Over the last three months, insiders sold 98,325 shares of company stock worth $6,504,426. Company insiders own 3.40% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on ITCI shares. Canaccord Genuity Group lifted their price target on Intra-Cellular Therapies from $100.00 to $107.00 and gave the company a “buy” rating in a report on Tuesday, April 23rd. TD Cowen boosted their target price on Intra-Cellular Therapies from $80.00 to $90.00 and gave the stock a “buy” rating in a research note on Wednesday, April 17th. Royal Bank of Canada restated an “outperform” rating and set a $86.00 target price on shares of Intra-Cellular Therapies in a research note on Wednesday, April 3rd. Cantor Fitzgerald restated an “overweight” rating and set a $120.00 target price on shares of Intra-Cellular Therapies in a research note on Wednesday, April 24th. Finally, The Goldman Sachs Group boosted their target price on Intra-Cellular Therapies from $67.00 to $77.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 17th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $90.17.

View Our Latest Analysis on ITCI

About Intra-Cellular Therapies

(Free Report)

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.

Read More

Want to see what other hedge funds are holding ITCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intra-Cellular Therapies, Inc. (NASDAQ:ITCIFree Report).

Institutional Ownership by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.